COPD exacerbation: Difference between revisions
No edit summary |
No edit summary |
||
| Line 1: | Line 1: | ||
==Background== | |||
*Airflow limitation (FEV1:FVC < 0.70) that is not fully reversible | |||
**Encompasses chronic bronchitis (85%) and emphysema (15%) | |||
*Acute exacerbations due to incr V/Q mismatch, not expiratory airflow limitation | |||
==Precipitants== | |||
#Infection (75%) | |||
##50% viral, 50% bacterial | |||
#Cold weather | |||
#B-blockers | |||
#Narcotics | |||
#Sedative-hypnotic agents | |||
#PTX | |||
#PE | |||
==Diagnosis== | ==Diagnosis== | ||
*Increase in cough, sputum, or dyspnea | *Increase in cough, sputum, or dyspnea | ||
* | *Hypoxemia | ||
** | **Tachypnea, tachycardia, HTN, cyanosis, AMS | ||
*Hypercapnia | |||
* | |||
** | |||
==Differential Diagnosis== | ==Differential Diagnosis== | ||
# CHF | #Ashtma | ||
# PE | ##More likely in younger pt (<50yo) | ||
# PNA | #CHF | ||
##Can coexist w/ COPD | |||
##Orthopnea, interstitial edema more c/w CHF | |||
##BNP >500 very likely to be CHF | |||
#PE | |||
##20% of pts w/ severe COPD exacerbation of unclear trigger have a PE | |||
#ACS | |||
#PTX | |||
##COPD is major risk factor for PTX | |||
#PNA | |||
##Frequently coexists w/ COPD exacerbation | |||
==Work-up== | ==Work-up== | ||
#VBG/ABG | |||
##Perform if SpO2 <90% or concerned about symptomatic hypercapnia | |||
#Peak flow | |||
##<100 indicates severe exacerbation | |||
#CXR | #CXR | ||
##Consider for | ##Consider if concerned for PNA or CHF | ||
#Sputum culture | #Sputum culture | ||
## | ##Usually not indicated except for pt w/ recent antibiotic failure | ||
###Risk factors for pseudomonas infection | ###Risk factors for pseudomonas infection | ||
###Recent hospitalization (>2 days within previous 3 months) | ####Recent hospitalization (>2 days within previous 3 months) | ||
###Frequent abx tx (>4 courses w/in past year) | ####Frequent abx tx (>4 courses w/in past year) | ||
###Severe underlying COPD (FEV1 < 50% predicted) | ####Severe underlying COPD (FEV1 < 50% predicted) | ||
###Previous isolation of pseudomonas | ####Previous isolation of pseudomonas | ||
==Treatment== | ==Treatment== | ||
#O2 | #O2 | ||
## | ##Maintain PaO2 of 60-70 or SpO2 90-94% | ||
##If unable to correct hypoxemia with a low FiO2 consider alternative diagnosis | ##If unable to correct hypoxemia with a low FiO2 consider alternative diagnosis | ||
##Adequate oxygenation is essential, even if it leads to hypercapnia | ##Adequate oxygenation is essential, even if it leads to hypercapnia | ||
##If hypercapnia leads to AMS, dysrhythmias, acidemia | ##If hypercapnia leads to AMS, dysrhythmias, or acidemia consider mechanical ventilation | ||
#Albuterol/ipratropium | #Albuterol/ipratropium | ||
#Steroids (no difference in efficacy between PO and IV) | #Steroids (no difference in efficacy between PO and IV) | ||
| Line 38: | Line 65: | ||
##IV: Methylprednisolone 60-125mg BID-QID | ##IV: Methylprednisolone 60-125mg BID-QID | ||
#Antibiotics | #Antibiotics | ||
##Indicated for | ##Indicated for: | ||
#Noninvasive ventilation ( | ###Increased sputum volume or change in color | ||
###Fever | |||
###Suspicion of infectious etiology of exacerbation | |||
#Noninvasive ventilation (CPAP or BiPaP) | |||
##CPAP: start at low level and titrate up to max 15 | |||
##BiPAP: Start IPAP 8 (max 20), EPAP 4 (max 15) | |||
##Contraindications: | |||
###Uncooperative or obtunded pt | |||
###Inability to clear secretios | |||
###Hemodynamic instability | |||
#Mechanical ventilation | |||
##Indications | |||
###Severe dyspnea w/ use of accessory muscles and paradoxical breathing | |||
###RR>35 bpm | |||
###PaO2 <50 or PaO2/FiO2 <200 | |||
###pH <7.25 and PaCO2 >60 | |||
###Altered mental status | |||
###Cardiovascular complications (hypotension, shock, CHF) | |||
===Outpatient=== | ===Outpatient=== | ||
#If pt has risk factors (Age >65, cardiac disease, >3 exacerbations per year): | #If pt has risk factors (Age >65, cardiac disease, >3 exacerbations per year): | ||
| Line 84: | Line 128: | ||
#Uncertain diagnosis | #Uncertain diagnosis | ||
#High risk comorbidities (e.g. PNA, CHF, renal failure) | #High risk comorbidities (e.g. PNA, CHF, renal failure) | ||
==Source== | ==Source== | ||
*NEJM 4/10 | *NEJM 4/10 | ||
Revision as of 03:58, 25 July 2011
Background
- Airflow limitation (FEV1:FVC < 0.70) that is not fully reversible
- Encompasses chronic bronchitis (85%) and emphysema (15%)
- Acute exacerbations due to incr V/Q mismatch, not expiratory airflow limitation
Precipitants
- Infection (75%)
- 50% viral, 50% bacterial
- Cold weather
- B-blockers
- Narcotics
- Sedative-hypnotic agents
- PTX
- PE
Diagnosis
- Increase in cough, sputum, or dyspnea
- Hypoxemia
- Tachypnea, tachycardia, HTN, cyanosis, AMS
- Hypercapnia
Differential Diagnosis
- Ashtma
- More likely in younger pt (<50yo)
- CHF
- Can coexist w/ COPD
- Orthopnea, interstitial edema more c/w CHF
- BNP >500 very likely to be CHF
- PE
- 20% of pts w/ severe COPD exacerbation of unclear trigger have a PE
- ACS
- PTX
- COPD is major risk factor for PTX
- PNA
- Frequently coexists w/ COPD exacerbation
Work-up
- VBG/ABG
- Perform if SpO2 <90% or concerned about symptomatic hypercapnia
- Peak flow
- <100 indicates severe exacerbation
- CXR
- Consider if concerned for PNA or CHF
- Sputum culture
- Usually not indicated except for pt w/ recent antibiotic failure
- Risk factors for pseudomonas infection
- Recent hospitalization (>2 days within previous 3 months)
- Frequent abx tx (>4 courses w/in past year)
- Severe underlying COPD (FEV1 < 50% predicted)
- Previous isolation of pseudomonas
- Risk factors for pseudomonas infection
Treatment
- O2
- Maintain PaO2 of 60-70 or SpO2 90-94%
- If unable to correct hypoxemia with a low FiO2 consider alternative diagnosis
- Adequate oxygenation is essential, even if it leads to hypercapnia
- If hypercapnia leads to AMS, dysrhythmias, or acidemia consider mechanical ventilation
- Albuterol/ipratropium
- Steroids (no difference in efficacy between PO and IV)
- Duration = 7-10d (no tapering required)
- Oral: Prednisone 40-60mg daily
- IV: Methylprednisolone 60-125mg BID-QID
- Antibiotics
- Indicated for:
- Increased sputum volume or change in color
- Fever
- Suspicion of infectious etiology of exacerbation
- Indicated for:
- Noninvasive ventilation (CPAP or BiPaP)
- CPAP: start at low level and titrate up to max 15
- BiPAP: Start IPAP 8 (max 20), EPAP 4 (max 15)
- Contraindications:
- Uncooperative or obtunded pt
- Inability to clear secretios
- Hemodynamic instability
- Mechanical ventilation
- Indications
- Severe dyspnea w/ use of accessory muscles and paradoxical breathing
- RR>35 bpm
- PaO2 <50 or PaO2/FiO2 <200
- pH <7.25 and PaCO2 >60
- Altered mental status
- Cardiovascular complications (hypotension, shock, CHF)
- Indications
Outpatient
- If pt has risk factors (Age >65, cardiac disease, >3 exacerbations per year):
- Levofloxacin/moxifloxacin OR amox/clavulanate
- No risk factors
- Azithromycin OR doxycline OR TMP/SMX
- Pseudomonas risk factors (see above)
- Ciprofloxacin
Maintenance
- B-agonist
- Short:albuterol 90µg/inh 1-2 q4-6h prn; neb 2.5mg q4-6h prn
- Long: Salmeterol 50µg/inh 1 bid
- Formoterol MDI 12µg/INH 1 bid; neb 20µg bid
- Arfomoterol neb 15µg bid
- Anticholinergic
- Short: ipratriopium 17µg/INH 2xINH 4x/d up to 12; neb 0.5mg q6-8h
- Long: tiotropium 18µg/INH 1xINH qam
- Steroids (inhaled)
- Fluticasone (dry powder) 250µg/INH 1-2 bid; (aerosol) 220µg 1-2INH bid
- Budesonide 160µk 2 inh bid
- Beclomethasone 80µg/inh 2INH bid
- Mometasone 220µg/INH 1-2INH bid
- Combination
- Albuterol-Ipratropium 90/18 2INH 4xd up to 12
- Advair Diskus = Fluticasone-salmeterol (dry powder): 250/50 1INH bid
- Budesonide-Formoterol: 160/4.5 2INH bid
- Home O2
- Indicated if PaO2 < 55mmHg or O2 Sat < 88% RA
- Goal is 18h/day including sleep with flow rate that maintain sat > 90%
Inpatient
- Pseudomonas risk factors:
- Levofloxacin PO or IV OR cefepime IV OR Ceftazadine IV OR pip-tazo IV
- No pseudomonas risk factors:
- Levo/moxifloxacin PO or IV OR CTX IV OR cefotaxime IV
- Consider oseltamivir during influenza season
Disposition
Consider hospitalization for the following:
- Inadequate response of symptoms to outpatient management
- Inability to eat or sleep due to symptoms
- Changes in mental status
- Uncertain diagnosis
- High risk comorbidities (e.g. PNA, CHF, renal failure)
Source
- NEJM 4/10
- UpToDate
- Tintinalli
